Join Growin Stock Community!

Kazia therapeutics limitedKZIA.US Overview

US StockHealthcare
(No presentation for KZIA)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

KZIA AI Insights

KZIA Overall Performance

KZIA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

KZIA Recent Performance

-4.85%

Kazia therapeutics limited

0.05%

Avg of Sector

-0.31%

S&P500

KZIA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

KZIA Key Information

KZIA Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

KZIA Profile

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Price of KZIA

KZIA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

KZIA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-12.60
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
52.37
PB Ratio
3.09
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-48582.97%
Revenue Growth (YoY)
-98.31%
Profit Growth (YoY)
-98.31%
3-Year Revenue Growth
314.15%
3-Year Profit Growth
314.15%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-12.60
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
52.37
PB Ratio
3.09
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-48582.97%
Revenue Growth (YoY)
-98.31%
Profit Growth (YoY)
-98.31%
3-Year Revenue Growth
314.15%
3-Year Profit Growth
314.15%

  • When is KZIA's latest earnings report released?

    The most recent financial report for Kazia therapeutics limited (KZIA) covers the period of 2025Q4 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating KZIA's short-term business performance and financial health. For the latest updates on KZIA's earnings releases, visit this page regularly.

  • What is the operating profit of KZIA?

    According to the latest financial report, Kazia therapeutics limited (KZIA) reported an Operating Profit of -4.85M with an Operating Margin of -24,599.78% this period, representing a growth of 75.24% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is KZIA's revenue growth?

    In the latest financial report, Kazia therapeutics limited (KZIA) announced revenue of 19.71K, with a Year-Over-Year growth rate of -99.21%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does KZIA have?

    At the end of the period, Kazia therapeutics limited (KZIA) held Total Cash and Cash Equivalents of 4.35M, accounting for 0.72 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is KZIA's EPS continuing to grow?

    According to the past four quarterly reports, Kazia therapeutics limited (KZIA)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -6.4. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of KZIA?

    Kazia therapeutics limited (KZIA)'s Free Cash Flow (FCF) for the period is 0, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 100% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.